Study of EMB-01 for advanced left-sided colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have left-sided colorectal cancer (from the splenic flexure to the rectum) that has spread or cannot be removed.
- You have had at least one standard treatment for advanced cancer, including chemotherapy and targeted therapy, but it stopped working or caused unacceptable side effects.
- You have not taken TAS-102, fruquintinib, or regorafenib before.
- You are willing to provide a tumor sample from a recent biopsy or one taken in the last 2 years.
- You have no KRAS, NRAS, or BRAF mutations, and your tumor is not HER2 positive or have certain other gene changes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DEM301 for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if DEM301 can help shrink or control the cancer.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.